6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

1028 trials found

diseases per page:

Showing 1 to 10 of 1,028 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05709301 (ClinicalTrials.gov)	April 1, 2023	11/1/2023	Randomized Clinical Trial of Donepezil for the Treatment of Mild Cognitive Impairment in Parkinson's ...	Multicenter, Randomized, Double-blinded, Placebo-controlled Clinical Trial of Donepezil for the Trea ...	Parkinson Disease;Mild Cognitive Impairment	Drug: Donepezil Hydrochloride;Drug: Placebo	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	NULL	Not yet recruiting	50 Years	80 Years	All	120	Phase 2	NULL
2	NCT05766813 (ClinicalTrials.gov)	March 2023	24/2/2023	Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkin ...	A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety o ...	Parkinson Disease	Drug: Lenrispodun;Drug: Placebo	Intra-Cellular Therapies, Inc.	NULL	Recruiting	40 Years	80 Years	All	132	Phase 2	United States
3	EUCTR2021-004849-20-AT (EUCTR)	13/12/2022	05/08/2022	A Study to Assess the Safety of BIIB122 Tablets and if it can Slow the Worsening of Early-Stage Park ...	A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficac ...	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's di ...	Product Name: BIIB122 Product Code: DNL151, DN0001575, DN1575 INN or Proposed INN: NA Other descriptive ...	Biogen Idec Research Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	640	Phase 2	United States;Spain;Austria;Israel;Italy;United Kingdom;France;Canada;Poland;Netherlands;Germany;Chi ...
4	NCT05642442 (ClinicalTrials.gov)	December 1, 2022	30/11/2022	A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease	A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, M ...	Parkinson Disease;Tremor	Drug: Placebo;Drug: Suvecaltamide	Jazz Pharmaceuticals	NULL	Recruiting	40 Years	80 Years	All	160	Phase 2	United States
5	NCT05197439 (ClinicalTrials.gov)	December 1, 2022	5/1/2022	Dexmedetomidine Prevents Postoperative Delirium After Deep Brain Stimulation in Patients With Parkin ...	Effect of Dexmedetomidine on Postoperative Delirium in Elderly Patients With Parkinson's Disease Und ...	Dexmedetomidine;Postoperative Delirium;Deep Brain Stimulation	Drug: Dexmedetomidine;Drug: 0.9% saline	Beijing Tiantan Hospital	NULL	Not yet recruiting	60 Years	N/A	All	192	N/A	China
6	NCT05550714 (ClinicalTrials.gov)	October 15, 2022	20/9/2022	Choice of Anesthesia in Microelectrode Recording Guided Deep Brain Stimulation for Parkinson's Disea ...	Choice of Anesthesia in Microelectrode Recording Guided Deep Brain Stimulation for Parkinson's Disea ...	PD - Parkinson's Disease;Dexmedetomidine;Desflurane;Deep Brain Stimulation	Drug: general anesthesia;Drug: Conscious sedation	Beijing Tiantan Hospital	NULL	Recruiting	50 Years	80 Years	All	188	N/A	China
7	NCT05603312 (ClinicalTrials.gov)	October 5, 2022	12/10/2022	A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinso ...	A Randomized, Double-Blind, Sham-Controlled Study to Evaluate the Safety and Tolerability of Glutami ...	Parkinson Disease	Genetic: AAV-GAD Dose 1;Genetic: AAV-GAD Dose 2;Procedure: Sham Surgery	MeiraGTx, LLC	NULL	Recruiting	25 Years	85 Years	All	14	Phase 1/Phase 2	United States
8	NCT05370079 (ClinicalTrials.gov)	September 16, 2022	6/5/2022	Control Cohort CTRL COH	Control Cohort CTRL COH	Parkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Diseas ...	Biological: Collection of biological sample (blood and/or CSF)	Hospices Civils de Lyon	NULL	Not yet recruiting	18 Years	N/A	All	350	N/A	France
9	NCT05418673 (ClinicalTrials.gov)	August 26, 2022	10/6/2022	A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Dise ...	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy ...	Parkinson Disease	Drug: BIIB122;Drug: BIIB122-Matching Placebo	Biogen	Denali Therapeutics Inc.	Recruiting	30 Years	80 Years	All	400	Phase 3	United States;France;Spain
10	NCT05357989 (ClinicalTrials.gov)	August 3, 2022	19/4/2022	A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Parti ...	A 6-month Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial Investigating the ...	Parkinson's Disease, Idiopathic	Drug: Buntanetap;Drug: Placebo	Annovis Bio Inc.	TFS Trial Form Support	Recruiting	40 Years	85 Years	All	450	Phase 3	United States;Germany;Hungary;Italy;Poland;Spain

First Previous1 2 3 4 5…103Next Last